We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+20.42%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$380M
Cap. Flow
-$843M
Cap. Flow %
-27.17%
Top 10 Hldgs %
37.76%
Holding
82
New
16
Increased
13
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$50.7M
2
CGON icon
CG Oncology
CGON
+$46.2M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$42.3M
4
LEGN icon
Legend Biotech
LEGN
+$41.1M
5
TMDX icon
Transmedics
TMDX
+$40.9M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$41.8M
2
LNTH icon
Lantheus
LNTH
+$30.7M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$30.6M
4
KROS icon
Keros Therapeutics
KROS
+$22.6M
5
AMGN icon
Amgen
AMGN
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 57.18%
2 Miscellaneous 42.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$10.2B
$122M 3.95%
1,842,515
+1,161,414
+171% +$50.7M
NBIX icon
2
Neurocrine Biosciences
NBIX
$15.7B
$101M 3.25%
730,209
+15,000
+2% +$2.05M
ARGX icon
3
argenx
ARGX
$64B
$86.5M 2.79%
219,824
+66,620
+43% +$25.8M
PCVX icon
4
Vaxcyte
PCVX
$8.9B
$82.8M 2.67%
1,212,703
-77,262
-6% -$5.35M
LEGN icon
5
Legend Biotech
LEGN
$3.87B
$69.8M 2.25%
1,243,795
+681,195
+121% +$41.1M
PEN icon
6
Penumbra
PEN
$12.7B
$66M 2.13%
295,892
+73,100
+33% +$18.1M
MRVI icon
7
Maravai LifeSciences
MRVI
$1.14B
$62.6M 2.02%
7,221,960
+2,181,325
+43% +$14.8M
VKTX icon
8
Viking Therapeutics
VKTX
$3.75B
$58.5M 1.88%
+713,100
New +$31.7M
XENE icon
9
Xenon Pharmaceuticals
XENE
$5.81B
$56.3M 1.81%
1,308,011
-339,300
-21% -$15.6M
IRTC icon
10
iRhythm Holdings
IRTC
$3.96B
$56.1M 1.81%
483,257
-84,900
-15% -$9.54M
ALGN icon
11
Align Technology
ALGN
$11.2B
$55.5M 1.79%
169,252
+22,939
+16% +$6.73M
GH icon
12
Guardant Health
GH
$21.7B
$51.1M 1.65%
2,476,804
+1,717,876
+226% +$36.8M
CGON icon
13
CG Oncology
CGON
$6.59B
$49.6M 1.6%
+1,130,235
New +$46.2M
KROS icon
14
Keros Therapeutics
KROS
$219M
$48.8M 1.57%
737,379
-381,582
-34% -$22.6M
TMDX icon
15
Transmedics
TMDX
$3.07B
$45.4M 1.46%
614,531
+496,830
+422% +$40.9M
AVDL
16
DELISTED
Avadel Pharmaceuticals
AVDL
$45.1M 1.45%
+2,668,549
New +$39.7M
GKOS icon
17
Glaukos
GKOS
$10.6B
$42.5M 1.37%
450,676
+207,916
+86% +$18.6M
FNA
18
DELISTED
Paragon 28, Inc.
FNA
$41.6M 1.34%
3,365,609
+3,785
+0.1% +$45K
ISRG icon
19
Intuitive Surgical
ISRG
$132B
$40.1M 1.29%
+100,500
New +$38M
DAWN
20
DELISTED
Day One Biopharmaceuticals
DAWN
$35.9M 1.16%
2,173,704
-2,041,869
-48% -$30.6M
FDMT icon
21
4D Molecular Therapeutics
FDMT
$810M
$33.5M 1.08%
+1,052,485
New +$26.9M
KIDS icon
22
OrthoPediatrics
KIDS
$617M
$32.3M 1.04%
1,107,770
– –
KRYS icon
23
Krystal Biotech
KRYS
$10.4B
$31.5M 1.02%
177,089
-19,111
-10% -$2.65M
RLAY icon
24
Relay Therapeutics
RLAY
$4.11B
$31.1M 1%
+3,743,999
New +$36.5M
IRWD icon
25
Ironwood Pharmaceuticals
IRWD
$682M
$30.4M 0.98%
+3,489,843
New +$42.3M
1
2 3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q1 2024 Portfolio in Review

As of Q1 2024, Braidwell held 82 positions worth $3.1B, up 14% from $2.72B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $843M in Q1 2024, closing 12 positions and reducing 14 holdings. Its most notable exit was Immunocore, an estimated $41.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 49% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in CG Oncology worth $49.6M.

  • Braidwell's largest Q1 2024 buy was CG Oncology: 1,130,235 shares worth $49.6M.
  • Braidwell added most to Apogee Therapeutics in Q1 2024, an estimated $50.7M increase.
  • Braidwell's biggest Q1 2024 reduction was Day One Biopharmaceuticals, cutting an estimated $30.6M.
  • Braidwell fully exited Immunocore in Q1 2024, selling an estimated $41.8M.
  • Braidwell's ten largest holdings make up 38% of its $3.1B portfolio in Q1 2024.
  • Braidwell opened 16 new positions and closed 12 in Q1 2024.
  • Braidwell's portfolio value rose 14% quarter-over-quarter to $3.1B.

Based on Braidwell's 13F filing for Q1 2024, filed 15 May 2024.